C—Side by side
Compare
Up to four peptides. Opinion rows are labeled. Copy the URL to share.
| Field | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Type | Approved Outside US | Investigational |
| Regulatory status | Approved outside US; not FDA-approved | Not FDA-approved; no verified marketing authorization |
| Compounding status | Not cleared (advisory panel rejected) | Off Category 2, review pending |
| FDA-approved indications | None | None |
| Categories | Immune | Immune |
| Claimed uses |
|
|
| Mechanism | Synthetic counterpart of an endogenous thymic peptide that modulates dendritic-cell and T-cell responses. Toll-like-receptor signaling is implicated in its immunomodulatory effects. | Human cathelicidin antimicrobial peptide with membrane-disrupting and immune-signaling activities. Its effects on inflammation and tissue repair are context dependent. |
| Evidence level | Human RCTs (approved use) | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Watch | Watch |
| Routes | — | — |
| WADA | Verify | Verify |
| Where it stands (opinion) | Human trials exist, but evidence varies substantially by disease. The December 2024 FDA advisory committee voted against adding thymosin alpha-1 forms to the 503A bulks list. | Published ulcer trials provide human evidence, but active trial status is unverified. FDA moved the nomination to its withdrawn table and still flags safety uncertainties, including nonclinical tumor-related concerns. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 0 |